- Home
- FERA vs SGMT Comparison
FERA vs SGMT Comparison
Compare FERA & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FERA
- SGMT
- Stock Information
- Founded
- FERA 2024
- SGMT 2006
- Country
- FERA Cayman Islands
- SGMT United States
- Employees
- FERA N/A
- SGMT N/A
- Industry
- FERA
- SGMT
- Sector
- FERA
- SGMT
- Exchange
- FERA Nasdaq
- SGMT Nasdaq
- Market Cap
- FERA 317.4M
- SGMT 269.2M
- IPO Year
- FERA 2025
- SGMT 2023
- Fundamental
- Price
- FERA N/A
- SGMT $8.30
- Analyst Decision
- FERA
- SGMT Strong Buy
- Analyst Count
- FERA 0
- SGMT 5
- Target Price
- FERA N/A
- SGMT $26.60
- AVG Volume (30 Days)
- FERA 5.2K
- SGMT 2.5M
- Earning Date
- FERA 01-01-0001
- SGMT 08-13-2025
- Dividend Yield
- FERA N/A
- SGMT N/A
- EPS Growth
- FERA N/A
- SGMT N/A
- EPS
- FERA N/A
- SGMT N/A
- Revenue
- FERA N/A
- SGMT N/A
- Revenue This Year
- FERA N/A
- SGMT N/A
- Revenue Next Year
- FERA N/A
- SGMT N/A
- P/E Ratio
- FERA N/A
- SGMT N/A
- Revenue Growth
- FERA N/A
- SGMT N/A
- 52 Week Low
- FERA $10.00
- SGMT $1.73
- 52 Week High
- FERA $10.60
- SGMT $10.43
- Technical
- Relative Strength Index (RSI)
- FERA N/A
- SGMT 61.00
- Support Level
- FERA N/A
- SGMT $7.51
- Resistance Level
- FERA N/A
- SGMT $8.61
- Average True Range (ATR)
- FERA 0.00
- SGMT 1.16
- MACD
- FERA 0.00
- SGMT -0.12
- Stochastic Oscillator
- FERA 0.00
- SGMT 43.73
About FERA Fifth Era Acquisition Corp I Class A Ordinary Shares
Fifth Era Acquisition Corp I is a blank check company.
About SGMT Sagimet Biosciences Inc. Series A
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.